---
title: "Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales"
description: "Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264214976.md"
published_at: "2025-11-04T12:09:12.000Z"
---

# Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales

)

Overview

-   Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales
-   Net income for Q3 2025 misses analyst expectations, larger loss reported
-   FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20

Outlook

-   Company expects FDA decision on sNDA by December 20, 2025
-   Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome
-   Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln

Result Drivers

-   U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS
-   INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q3 $51.29

Product mln

Revenue

Q3 Net Miss -$52.90 -$45.50

Income mln mln (11

Analysts

)

Q3 Basic -$0.82

### EPS

### Q3 -$52.65

Operatin mln

g Income

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 14 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the pharmaceuticals peer group is “buy”
-   Wall Street’s median 12-month price target for Rhythm Pharmaceuticals Inc is $121.50, about 6.4% above its November 3 closing price of $113.74

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [RYTM.US - Rhythm Pharma](https://longbridge.com/en/quote/RYTM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Rhythm Pharma｜8-K：2025 财年 Q4 营收 57 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/272088207.md) |
| 在 2025 年强劲的 IMCIVREE 收入指引后，评估 Rhythm Pharmaceuticals（RYTM）的估值 | Rhythm Pharmaceuticals (RYTM) 发布了其药物 IMCIVREE 的强劲初步收入指引，预计 2025 年第四季度的净产品收入约为 5700 万美元，比第三季度增长 11%，全年收入预计为 1.94 亿美元，较 20 | [Link](https://longbridge.com/en/news/272952447.md) |
| Latch｜10-Q：2025 财年 Q3 营收 17.43 百万美元 |  | [Link](https://longbridge.com/en/news/275617902.md) |
| 中国央行：初步统计，2026 年 1 月末社会融资规模存量为 449.11 万亿元，同比增长 8.2% | 中国央行：初步统计，2026 年 1 月末社会融资规模存量为 449.11 万亿元，同比增长 8.2%。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的 | [Link](https://longbridge.com/en/news/275875263.md) |
| AI 需求爆发，韩企北美销售额增长 14%，海力士在美销售额大增 65% | 据韩国科技媒体 ETNews 报道，受全球人工智能基础设施投资热潮驱动，韩国企业 2025 年前三季度在北美市场销售额同比增长 14.1%，达 343.8 万亿韩元。IT 与电子板块成为主要增长引擎，销售额增长 20.7%。SK 海力士在美 | [Link](https://longbridge.com/en/news/275440742.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.